Davita Inc vs Kohl's Corporation — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Kohl's Corporation trades at $20.2 (market cap $2.28B). The key difference: Davita Inc is far larger — about 5× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.49% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Kohl's Corporation for 48 Days on average.
| DVA | KSS | |
|---|---|---|
Market Cap | $11.29B | $2.28B |
Volume | 582,204 | 4,960,280 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $24.71 |
52-Week Low | $103.87 | $11.72 |
Typical Hold Time | 113 Days | 48 Days |
Enterprise Value | $24.01B | $7.88B |
Dividend Yield | — | 2.49% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Kohl's (KSS) trades at $20.12, up 2.5% today, with a bullish technical signal driven by moving averages but overbought RSI readings. The stock shows deep value with a P/E of 8.63 and P/B of 0.55, though revenue has declined annually since 2022. Recent Q2 2026 earnings beat estimates with EPS of $1.28, and the company raised full-year guidance, supported by margin gains and a new chief merchandising officer appointment.
The outlook is mixed: low valuation and earnings momentum offer upside, but persistent sales declines and competitive pressures pose risks. Analyst consensus is cautious with a $15.50 price target below the current price, reflecting skepticism about the sustainability of the turnaround amid consumer spending shifts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →